secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0000882095-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q4 2022 rev $7.4B, EPS $1.30; ex-Veklury sales +9%; FY 2023 guidance $26.0-26.5B product sales
--------------------------------------------------------------------------------

- Q4 revenue $7.4B (+2%); product sales ex-Veklury +9% to $6.3B.
- GAAP diluted EPS Q4 $1.30 vs $0.30; non-GAAP $1.67 vs $0.69.
- FY 2022 Biktarvy sales $10.4B (+20%); Trodelvy $680M (+79%); Cell Therapy $1.5B (+68%).
- FY 2023 guidance: product sales $26.0-26.5B; GAAP EPS $5.30-5.70; non-GAAP EPS $6.60-7.00.
- Q4 operating cash flow $2.6B; dividends $916M; share repurchases $791M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/0000882095-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/gild-20230202.htm
  HTML page:      https://secwatch.observer/filing/0000882095-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer